Orthofix Medical (OFIX) Financials

$11.51 -0.48 (-4.00%)

Closing price 05/21/2025 04:00 PM Eastern

Extended Trading

$11.51 0.00 (0.00%)

As of 05/21/2025 04:04 PM Eastern

Annual Income Statements for Orthofix Medical

This table shows Orthofix Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-126	-151	-20
Consolidated Net Income / (Loss)	-126	-151	-20
Net Income / (Loss) Continuing Operations	-126	-151	-20
Total Pre-Tax Income	-124	-149	-18
Total Operating Income	-85	-139	-13
Total Gross Profit	546	486	337
Total Revenue	799	745	461
Operating Revenue	799	745	461
Total Cost of Revenue	254	260	124
Operating Cost of Revenue	254	260	124
Total Operating Expenses	631	625	350
Selling, General & Admin Expense	533	530	309
Research & Development Expense	74	80	49
Amortization Expense	24	15	-7.40
Total Other Income / (Expense), net	-39	-9.57	-4.44
Interest Expense	30	8.63	1.29
Other Income / (Expense), net	-9.63	-0.94	-3.15
Income Tax Expense	2.12	2.72	2.04
Basic Earnings per Share	($3.30)	($4.12)	($0.98)
Weighted Average Basic Shares Outstanding	38.13M	36.73M	20.05M
Diluted Earnings per Share	($3.30)	($4.12)	($0.98)
Weighted Average Diluted Shares Outstanding	38.13M	36.73M	20.05M
Weighted Average Basic & Diluted Shares Outstanding	39.02M	37.41M	36.46M

This table shows Orthofix Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-29	-27	-33	-36	-22	-29	-39	-61	-7.06	-11
Consolidated Net Income / (Loss)	-29	-27	-33	-36	-22	-29	-39	-61	-7.06	-11
Net Income / (Loss) Continuing Operations	-29	-27	-33	-36	-22	-29	-39	-61	-7.06	-11
Total Pre-Tax Income	-30	-27	-32	-35	-22	-28	-38	-60	-6.99	-9.37
Total Operating Income	-11	-19	-25	-29	-18	-24	-37	-60	-11	-5.79
Total Gross Profit	149	135	135	127	137	120	120	110	89	83
Total Revenue	216	197	199	189	199	184	187	175	122	114
Operating Revenue	216	197	199	189	199	184	187	175	122	114
Total Cost of Revenue	67	62	64	61	64	64	67	65	33	31
Operating Cost of Revenue	67	62	64	61	64	64	67	65	33	31
Total Operating Expenses	160	154	160	157	155	144	156	170	100	89
Selling, General & Admin Expense	433	34	34	32	420	27	34	49	254	19
Research & Development Expense	19	17	18	19	19	19	19	23	13	12
Amortization Expense	5.03	6.52	7.39	5.40	3.72	3.57	3.33	4.13	2.27	2.48
Total Other Income / (Expense), net	-18	-7.74	-7.45	-5.83	-3.73	-3.94	-1.29	-0.61	4.06	-3.59
Interest Expense	15	5.21	4.94	4.56	4.50	1.58	1.27	1.29	0.23	0.28
Other Income / (Expense), net	-3.31	-2.53	-2.51	-1.27	0.77	-2.36	-0.02	0.68	4.29	-3.31
Income Tax Expense	-0.56	0.75	1.08	0.85	0.13	0.47	1.51	0.61	0.08	1.34
Basic Earnings per Share	($0.76)	($0.71)	($0.88)	($0.95)	($0.57)	($0.77)	($1.07)	($1.71)	($0.35)	($0.53)
Weighted Average Basic Shares Outstanding	38.13M	38.49M	38.02M	37.74M	36.73M	37.25M	36.76M	35.73M	20.05M	20.09M
Diluted Earnings per Share	($0.76)	($0.71)	($0.88)	($0.95)	($0.57)	($0.77)	($1.07)	($1.71)	($0.35)	($0.53)
Weighted Average Diluted Shares Outstanding	38.13M	38.49M	38.02M	37.74M	36.73M	37.25M	36.76M	35.73M	20.05M	20.09M
Weighted Average Basic & Diluted Shares Outstanding	39.02M	38.21M	38.17M	37.53M	37.41M	36.76M	36.74M	36.54M	36.46M	20.01M

This table details how cash moves in and out of Orthofix Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	48	-13	-37
Net Cash From Operating Activities	26	-46	-12
Net Cash From Continuing Operating Activities	26	-46	-12
Net Income / (Loss) Continuing Operations	-126	-151	-20
Consolidated Net Income / (Loss)	-126	-151	-20
Depreciation Expense	60	53	29
Amortization Expense	28	44	3.06
Non-Cash Adjustments To Reconcile Net Income	74	65	37
Changes in Operating Assets and Liabilities, net	-10	-56	-61
Net Cash From Investing Activities	-28	-33	-25
Net Cash From Continuing Investing Activities	-28	-33	-25
Purchase of Property, Plant & Equipment	-35	-62	-23
Acquisitions	0.00	0.00	-1.50
Divestitures	0.00	29	0.00
Sale and/or Maturity of Investments	7.40	0.00	0.13
Other Investing Activities, net	-0.10	-0.50	0.00
Net Cash From Financing Activities	51	65	-0.08
Net Cash From Continuing Financing Activities	51	65	-0.08
Repayment of Debt	-146	-82	-0.09
Payment of Dividends	0.00	-27	0.00
Issuance of Debt	198	175	0.00
Issuance of Common Equity	6.26	5.13	4.34
Other Financing Activities, net	-7.02	-5.05	-4.32
Effect of Exchange Rate Changes	-0.94	0.62	-1.00

This table details how cash moves in and out of Orthofix Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	53	3.69	-0.60	-8.29	4.09	-3.94	-12	-0.73	-0.96	-7.88
Net Cash From Operating Activities	24	12	8.98	-19	-6.69	0.48	-5.52	-34	2.35	-1.26
Net Cash From Continuing Operating Activities	24	12	8.98	-19	-6.69	0.48	-5.52	-34	2.35	-1.26
Net Income / (Loss) Continuing Operations	-29	-27	-33	-36	-22	-29	-39	-61	-7.06	-11
Consolidated Net Income / (Loss)	-29	-27	-33	-36	-22	-29	-39	-61	-7.06	-11
Depreciation Expense	16	15	14	15	14	13	13	13	7.42	7.57
Amortization Expense	14	4.66	4.56	4.53	10	9.11	11	13	0.74	0.75
Non-Cash Adjustments To Reconcile Net Income	14	17	25	18	7.07	15	23	20	11	8.58
Changes in Operating Assets and Liabilities, net	8.39	2.21	-1.32	-20	-16	-7.97	-13	-19	-9.44	-7.45
Net Cash From Investing Activities	-1.14	-5.86	-9.72	-11	-15	-22	-13	17	-5.90	-5.47
Net Cash From Continuing Investing Activities	-1.14	-5.86	-9.72	-11	-15	-22	-13	17	-5.90	-5.47
Purchase of Property, Plant & Equipment	-9.67	-5.32	-9.34	-11	-16	-22	-12	-11	-7.00	-5.13
Acquisitions	1.14	-0.49	-0.37	-0.27	1.30	-0.47	-0.47	-0.36	1.10	-0.43
Net Cash From Financing Activities	31	-2.46	0.23	21	25	18	5.81	16	1.50	-0.25
Net Cash From Continuing Financing Activities	31	-2.46	0.23	21	25	18	5.81	16	1.50	-0.25
Repayment of Debt	-129	-0.23	-0.85	-17	-55	-0.42	-0.28	-27	-0.02	-0.02
Issuance of Debt	158	-	-	40	105	19	6.00	45	-	-
Issuance of Common Equity	2.95	0.12	3.19	0.00	2.75	-	2.38	0.00	1.94	-
Other Financing Activities, net	-0.55	-2.35	-2.12	-2.00	-0.31	-0.33	-2.29	-2.12	-0.42	-0.23
Effect of Exchange Rate Changes	-0.90	0.34	-0.09	-0.28	0.56	-0.33	0.17	0.22	1.09	-0.89

This table presents Orthofix Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	893	925	459
Total Current Assets	433	420	256
Cash & Equivalents	83	33	51
Restricted Cash	2.50	4.65	0.00
Accounts Receivable	135	128	83
Inventories, net	189	222	100
Prepaid Expenses	23	32	22
Plant, Property, & Equipment, net	140	159	58
Total Noncurrent Assets	320	346	144
Goodwill	195	195	71
Intangible Assets	99	117	47
Other Noncurrent Operating Assets	26	33	26
Total Liabilities & Shareholders' Equity	893	925	459
Total Liabilities	390	327	122
Total Current Liabilities	169	165	84
Short-Term Debt	0.00	1.25	0.00
Accounts Payable	49	58	28
Other Current Liabilities	120	106	56
Total Noncurrent Liabilities	222	161	38
Long-Term Debt	157	93	0.00
Other Noncurrent Operating Liabilities	65	68	38
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	503	599	337
Total Preferred & Common Equity	503	599	337
Total Common Equity	503	599	337
Common Stock	784	750	337
Retained Earnings	-276	-150	1.25
Accumulated Other Comprehensive Income / (Loss)	-4.30	-1.29	-1.38

This table presents Orthofix Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	868	882	906	906	901	917	450
Total Current Assets	386	386	399	394	399	410	247
Cash & Equivalents	30	26	27	34	38	50	52
Restricted Cash	2.50	2.50	2.50	-	-	-	-
Accounts Receivable	125	125	126	114	112	113	76
Inventories, net	206	210	219	222	222	222	100
Prepaid Expenses	23	22	25	24	27	25	19
Plant, Property, & Equipment, net	147	154	158	153	141	137	58
Total Noncurrent Assets	335	342	349	359	361	370	145
Goodwill	195	195	195	195	192	203	71
Intangible Assets	105	108	113	121	126	122	48
Noncurrent Deferred & Refundable Income Taxes	0.00	0.00	0.00	0.00	0.00	0.00	1.54
Other Noncurrent Operating Assets	35	39	41	43	44	45	25
Total Liabilities & Shareholders' Equity	868	882	906	906	901	917	450
Total Liabilities	342	336	336	290	261	253	116
Total Current Liabilities	162	156	151	153	142	138	78
Short-Term Debt	6.25	4.69	3.13	-	-	-	-
Accounts Payable	47	50	57	53	51	46	28
Other Current Liabilities	109	101	90	99	90	92	50
Total Noncurrent Liabilities	180	180	185	138	119	115	38
Long-Term Debt	112	113	115	70	51	45	-
Other Noncurrent Operating Liabilities	68	67	70	68	68	70	38
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	526	546	570	615	640	664	334
Total Preferred & Common Equity	526	546	570	615	640	664	334
Total Common Equity	526	546	570	615	640	664	334
Common Stock	774	768	757	745	739	725	330
Retained Earnings	-247	-220	-186	-128	-99	-60	8.31
Accumulated Other Comprehensive Income / (Loss)	-0.90	-2.73	-0.66	-1.86	-0.11	-0.95	-5.16

This table displays calculated financial ratios and metrics derived from Orthofix Medical's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	7.27%	61.77%	-0.81%
EBITDA Growth	85.97%	-377.47%	-26.96%
EBIT Growth	32.71%	-753.02%	-40.83%
NOPAT Growth	39.17%	-948.46%	-59.57%
Net Income Growth	16.78%	-666.60%	48.54%
EPS Growth	19.90%	-320.41%	49.74%
Operating Cash Flow Growth	156.37%	-296.54%	-162.45%
Free Cash Flow Firm Growth	104.65%	-906.34%	-1,002.75%
Invested Capital Growth	-12.35%	129.01%	14.88%
Revenue Q/Q Growth	2.12%	11.50%	-0.61%
EBITDA Q/Q Growth	59.89%	10.42%	16.95%
EBIT Q/Q Growth	2.84%	-8.35%	12.80%
NOPAT Q/Q Growth	7.48%	-5.52%	-14.61%
Net Income Q/Q Growth	-5.86%	-11.09%	56.59%
EPS Q/Q Growth	-6.11%	-5.64%	60.96%
Operating Cash Flow Q/Q Growth	656.54%	-24.63%	-447.60%
Free Cash Flow Firm Q/Q Growth	190.27%	-0.93%	-454.23%
Invested Capital Q/Q Growth	-6.12%	0.54%	1.52%
Profitability Metrics	-	-	-
Gross Margin	68.28%	65.24%	73.18%
EBITDA Margin	-0.76%	-5.83%	3.40%
Operating Margin	-10.58%	-18.66%	-2.88%
EBIT Margin	-11.79%	-18.79%	-3.56%
Profit (Net Income) Margin	-15.76%	-20.31%	-4.29%
Tax Burden Percent	101.71%	101.88%	111.54%
Interest Burden Percent	131.44%	106.10%	107.85%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-9.63%	-20.69%	-3.47%
ROIC Less NNEP Spread (ROIC-NNEP)	-114.05%	-1,851.80%	11.63%
Return on Net Nonoperating Assets (RNNOA)	-13.24%	-11.68%	-2.39%
Return on Equity (ROE)	-22.87%	-32.36%	-5.86%
Cash Return on Invested Capital (CROIC)	3.53%	-99.11%	-17.32%
Operating Return on Assets (OROA)	-10.36%	-20.24%	-3.51%
Return on Assets (ROA)	-13.86%	-21.88%	-4.22%
Return on Common Equity (ROCE)	-22.87%	-32.36%	-5.86%
Return on Equity Simple (ROE_SIMPLE)	-25.04%	-25.29%	-5.86%
Net Operating Profit after Tax (NOPAT)	-59	-97	-9.29
NOPAT Margin	-7.41%	-13.07%	-2.02%
Net Nonoperating Expense Percent (NNEP)	104.42%	1,831.12%	-15.10%
Return On Investment Capital (ROIC_SIMPLE)	-8.97%	-14.05%	-2.76%
Cost of Revenue to Revenue	31.72%	34.93%	26.82%
SG&A Expenses to Revenue	66.61%	71.16%	67.02%
R&D to Revenue	9.21%	10.76%	10.65%
Operating Expenses to Revenue	78.86%	83.91%	76.06%
Earnings before Interest and Taxes (EBIT)	-94	-140	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.09	-43	16
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.33	0.83	1.22
Price to Tangible Book Value (P/TBV)	3.19	1.73	1.88
Price to Revenue (P/Rev)	0.83	0.66	0.89
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.29	0.84	1.26
Enterprise Value to Revenue (EV/Rev)	0.92	0.74	0.78
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	23.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	28.64	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	34.04	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.31	0.16	0.00
Long-Term Debt to Equity	0.31	0.16	0.00
Financial Leverage	0.12	0.01	-0.21
Leverage Ratio	1.65	1.48	1.39
Compound Leverage Factor	2.17	1.57	1.50
Debt to Total Capital	23.79%	13.61%	0.00%
Short-Term Debt to Total Capital	0.00%	0.18%	0.00%
Long-Term Debt to Total Capital	23.79%	13.43%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	76.21%	86.39%	100.00%
Debt to EBITDA	-25.77	-2.17	0.00
Net Debt to EBITDA	-11.70	-1.30	0.00
Long-Term Debt to EBITDA	-25.77	-2.14	0.00
Debt to NOPAT	-2.65	-0.97	0.00
Net Debt to NOPAT	-1.20	-0.58	0.00
Long-Term Debt to NOPAT	-2.65	-0.96	0.00
Altman Z-Score	1.50	1.32	3.37
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.57	2.54	3.06
Quick Ratio	1.29	0.98	1.60
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	22	-467	-46
Operating Cash Flow to CapEx	73.95%	-73.74%	-49.82%
Free Cash Flow to Firm to Interest Expense	0.73	-54.05	-35.99
Operating Cash Flow to Interest Expense	0.87	-5.30	-8.96
Operating Cash Flow Less CapEx to Interest Expense	-0.31	-12.49	-26.94
Efficiency Ratios	-	-	-
Asset Turnover	0.88	1.08	0.99
Accounts Receivable Turnover	6.08	7.07	5.71
Inventory Turnover	1.23	1.62	1.35
Fixed Asset Turnover	5.35	6.86	7.84
Accounts Payable Turnover	4.73	6.06	4.57
Days Sales Outstanding (DSO)	59.99	51.66	63.94
Days Inventory Outstanding (DIO)	296.21	225.92	270.51
Days Payable Outstanding (DPO)	77.11	60.25	79.85
Cash Conversion Cycle (CCC)	279.09	217.33	254.60
Capital & Investment Metrics	-	-	-
Invested Capital	574	655	286
Invested Capital Turnover	1.30	1.58	1.72
Increase / (Decrease) in Invested Capital	-81	369	37
Enterprise Value (EV)	738	552	360
Market Capitalization	667	495	411
Book Value per Share	$13.17	$16.29	$16.84
Tangible Book Value per Share	$5.48	$7.79	$10.90
Total Capital	660	693	337
Total Debt	157	94	0.00
Total Long-Term Debt	157	93	0.00
Net Debt	71	57	-51
Capital Expenditures (CapEx)	35	62	23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	179	219	122
Debt-free Net Working Capital (DFNWC)	265	256	172
Net Working Capital (NWC)	265	255	172
Net Nonoperating Expense (NNE)	67	54	10
Net Nonoperating Obligations (NNO)	71	57	-51
Total Depreciation and Amortization (D&A)	88	97	32
Debt-free, Cash-free Net Working Capital to Revenue	22.38%	29.35%	26.41%
Debt-free Net Working Capital to Revenue	33.10%	34.41%	37.41%
Net Working Capital to Revenue	33.10%	34.24%	37.41%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($3.30)	($4.12)	($0.98)
Adjusted Weighted Average Basic Shares Outstanding	38.13M	36.73M	20.05M
Adjusted Diluted Earnings per Share	($3.30)	($4.12)	($0.98)
Adjusted Weighted Average Diluted Shares Outstanding	38.13M	36.73M	20.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.02M	37.41M	36.46M
Normalized Net Operating Profit after Tax (NOPAT)	-59	-97	-9.29
Normalized NOPAT Margin	-7.41%	-13.07%	-2.02%
Pre Tax Income Margin	-15.49%	-19.94%	-3.84%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-3.18	-16.23	-12.75
NOPAT to Interest Expense	-2.00	-11.28	-7.21
EBIT Less CapEx to Interest Expense	-4.36	-23.42	-30.73
NOPAT Less CapEx to Interest Expense	-3.18	-18.47	-25.19
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	-17.77%	0.00%
Augmented Payout Ratio	0.00%	-17.77%	0.00%

This table displays calculated financial ratios and metrics derived from Orthofix Medical's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	8.33%	6.85%	6.20%	7.65%	62.88%	61.41%	58.39%	64.64%	-2.27%	1.39%
EBITDA Growth	141.10%	65.42%	27.94%	66.02%	361.37%	-497.15%	-214.19%	-868.28%	260.51%	-113.03%
EBIT Growth	15.72%	20.08%	25.20%	48.15%	-159.68%	-194.77%	-1,162.68%	-1,370.80%	26.29%	-332.68%
NOPAT Growth	37.34%	22.70%	32.01%	50.87%	-65.84%	-322.48%	-571.91%	-1,840.03%	-18.08%	-1,748.88%
Net Income Growth	-31.44%	5.09%	15.18%	40.89%	-213.99%	-169.29%	-1,684.01%	-1,266.32%	78.48%	-393.60%
EPS Growth	-33.33%	7.79%	17.76%	44.44%	-62.86%	-45.28%	-991.67%	-677.27%	81.38%	-581.82%
Operating Cash Flow Growth	454.50%	2,346.75%	262.87%	45.34%	-385.09%	137.74%	-12.27%	-341.30%	-80.07%	-119.65%
Free Cash Flow Firm Growth	119.08%	106.91%	100.20%	95.34%	-752.59%	-8,876.44%	-8,387.33%	-7,126.73%	-1,116.21%	40.45%
Invested Capital Growth	-12.35%	-6.13%	-2.79%	-0.02%	129.01%	131.24%	131.36%	150.02%	14.88%	0.09%
Revenue Q/Q Growth	9.69%	-1.01%	5.31%	-5.26%	8.19%	-1.61%	6.74%	43.34%	7.22%	-3.45%
EBITDA Q/Q Growth	1,076.82%	81.97%	21.34%	-274.02%	240.10%	62.43%	62.91%	-2,463.09%	281.32%	-107.19%
EBIT Q/Q Growth	30.97%	21.84%	10.44%	-74.43%	34.54%	26.86%	37.92%	-773.60%	25.70%	-363.70%
NOPAT Q/Q Growth	39.27%	24.12%	15.10%	-60.18%	25.09%	33.26%	38.65%	-440.69%	-90.84%	-174.55%
Net Income Q/Q Growth	-6.42%	18.11%	7.15%	-62.44%	23.16%	26.81%	35.30%	-762.90%	34.10%	-530.53%
EPS Q/Q Growth	-7.04%	19.32%	7.37%	-66.67%	25.97%	28.04%	37.43%	-388.57%	33.96%	-541.67%
Operating Cash Flow Q/Q Growth	103.32%	29.91%	148.31%	-177.79%	-1,503.35%	108.65%	83.79%	-1,548.89%	285.76%	74.27%
Free Cash Flow Firm Q/Q Growth	172.45%	3,232.80%	103.94%	94.66%	1.31%	2.41%	9.31%	-876.11%	-939.07%	-190.10%
Invested Capital Q/Q Growth	-6.12%	-3.67%	-3.63%	0.57%	0.54%	-0.24%	-0.88%	130.36%	1.52%	-0.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.02%	68.69%	67.84%	67.46%	68.63%	65.09%	63.93%	62.97%	72.96%	73.18%
EBITDA Margin	7.21%	-0.81%	-4.45%	-5.95%	3.24%	-2.50%	-6.55%	-18.86%	1.14%	-0.68%
Operating Margin	-5.32%	-9.61%	-12.54%	-15.55%	-9.20%	-13.29%	-19.59%	-34.08%	-9.04%	-5.08%
EBIT Margin	-6.86%	-10.90%	-13.80%	-16.23%	-8.82%	-14.57%	-19.60%	-33.70%	-5.53%	-7.98%
Profit (Net Income) Margin	-13.52%	-13.93%	-16.84%	-19.10%	-11.14%	-15.68%	-21.08%	-34.78%	-5.78%	-9.40%
Tax Burden Percent	98.10%	102.82%	103.35%	102.42%	100.95%	101.66%	103.98%	101.01%	101.07%	114.34%
Interest Burden Percent	200.88%	124.32%	118.03%	114.89%	125.17%	105.88%	103.45%	102.18%	103.39%	103.05%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-4.84%	-8.34%	-10.50%	-12.53%	-10.20%	-13.32%	-17.54%	-27.38%	-10.89%	-5.85%
ROIC Less NNEP Spread (ROIC-NNEP)	-37.86%	-31.50%	-41.72%	-49.50%	-327.26%	139.95%	42.21%	22.41%	-11.85%	4.04%
Return on Net Nonoperating Assets (RNNOA)	-4.39%	-3.37%	-3.61%	-3.36%	-2.06%	-2.26%	-1.98%	-1.72%	2.44%	-0.78%
Return on Equity (ROE)	-9.24%	-11.71%	-14.10%	-15.89%	-12.26%	-15.58%	-19.52%	-29.10%	-8.45%	-6.63%
Cash Return on Invested Capital (CROIC)	3.53%	-3.80%	-7.71%	-11.53%	-99.11%	-99.01%	-96.22%	-96.32%	-17.32%	-2.97%
Operating Return on Assets (OROA)	-6.03%	-9.62%	-11.93%	-13.51%	-9.49%	-14.37%	-17.21%	-25.87%	-5.45%	-7.79%
Return on Assets (ROA)	-11.88%	-12.30%	-14.55%	-15.89%	-12.00%	-15.47%	-18.51%	-26.71%	-5.69%	-9.17%
Return on Common Equity (ROCE)	-9.24%	-11.71%	-14.10%	-15.89%	-12.26%	-15.58%	-19.52%	-29.10%	-8.45%	-6.63%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-22.63%	-22.07%	-22.18%	0.00%	-22.14%	-18.46%	-11.48%	0.00%	-13.64%
Net Operating Profit after Tax (NOPAT)	-8.03	-13	-17	-21	-13	-17	-26	-42	-7.73	-4.05
NOPAT Margin	-3.73%	-6.73%	-8.78%	-10.89%	-6.44%	-9.30%	-13.71%	-23.86%	-6.32%	-3.55%
Net Nonoperating Expense Percent (NNEP)	33.02%	23.16%	31.23%	36.97%	317.07%	-153.27%	-59.74%	-49.78%	0.97%	-9.88%
Return On Investment Capital (ROIC_SIMPLE)	-1.22%	-	-	-	-1.85%	-	-	-	-2.30%	-
Cost of Revenue to Revenue	30.98%	31.31%	32.16%	32.54%	32.04%	34.91%	36.07%	37.03%	27.04%	26.82%
SG&A Expenses to Revenue	200.93%	17.07%	17.12%	16.78%	211.11%	14.75%	18.27%	27.86%	208.04%	16.95%
R&D to Revenue	8.72%	8.80%	9.09%	10.33%	9.51%	10.09%	10.39%	13.30%	10.76%	10.48%
Operating Expenses to Revenue	74.34%	78.30%	80.38%	83.02%	77.83%	78.37%	83.51%	97.05%	81.99%	78.26%
Earnings before Interest and Taxes (EBIT)	-15	-21	-27	-31	-18	-27	-37	-59	-6.76	-9.10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	16	-1.59	-8.83	-11	6.45	-4.60	-12	-33	1.40	-0.77
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.33	1.13	0.91	0.95	0.83	0.77	1.03	0.92	1.22	1.15
Price to Tangible Book Value (P/TBV)	3.19	2.63	2.05	2.07	1.73	1.58	2.05	1.80	1.88	1.78
Price to Revenue (P/Rev)	0.83	0.76	0.65	0.72	0.66	0.71	1.10	1.15	0.89	0.82
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.29	1.12	0.92	0.96	0.84	0.78	1.03	0.92	1.26	1.17
Enterprise Value to Revenue (EV/Rev)	0.92	0.87	0.76	0.83	0.74	0.76	1.13	1.14	0.78	0.71
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	23.00	24.69
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	28.64	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	34.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.31	0.23	0.22	0.21	0.16	0.11	0.08	0.07	0.00	0.00
Long-Term Debt to Equity	0.31	0.21	0.21	0.20	0.16	0.11	0.08	0.07	0.00	0.00
Financial Leverage	0.12	0.11	0.09	0.07	0.01	-0.02	-0.05	-0.08	-0.21	-0.19
Leverage Ratio	1.65	1.55	1.50	1.48	1.48	1.43	1.39	1.38	1.39	1.36
Compound Leverage Factor	3.32	1.93	1.77	1.70	1.85	1.51	1.44	1.41	1.44	1.40
Debt to Total Capital	23.79%	18.38%	17.77%	17.17%	13.61%	10.21%	7.38%	6.35%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.97%	0.71%	0.45%	0.18%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	23.79%	17.41%	17.07%	16.71%	13.43%	10.21%	7.38%	6.35%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	76.21%	81.62%	82.23%	82.83%	86.39%	89.79%	92.62%	93.65%	100.00%	100.00%
Debt to EBITDA	-25.77	-7.80	-6.48	-5.46	-2.17	-1.44	-1.14	-2.08	0.00	0.00
Net Debt to EBITDA	-11.70	-5.65	-4.90	-4.10	-1.30	-0.75	-0.30	0.23	0.00	0.00
Long-Term Debt to EBITDA	-25.77	-7.39	-6.22	-5.32	-2.14	-1.44	-1.14	-2.08	0.00	0.00
Debt to NOPAT	-2.65	-1.85	-1.74	-1.55	-0.97	-0.76	-0.64	-0.92	0.00	0.00
Net Debt to NOPAT	-1.20	-1.34	-1.31	-1.17	-0.58	-0.39	-0.17	0.10	0.00	0.00
Long-Term Debt to NOPAT	-2.65	-1.75	-1.67	-1.51	-0.96	-0.76	-0.64	-0.92	0.00	0.00
Altman Z-Score	1.79	1.78	1.62	1.74	1.76	1.74	2.23	2.08	3.43	3.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.57	2.39	2.48	2.65	2.54	2.58	2.82	2.98	3.06	3.18
Quick Ratio	1.29	0.96	0.97	1.01	0.98	0.97	1.06	1.19	1.60	1.64
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	73	27	0.80	-20	-382	-387	-397	-437	-45	-4.31
Operating Cash Flow to CapEx	245.47%	219.30%	96.15%	-176.37%	-40.93%	2.18%	-44.66%	-296.55%	33.54%	-24.65%
Free Cash Flow to Firm to Interest Expense	4.89	5.14	0.16	-4.47	-84.89	-245.59	-313.28	-339.28	-195.65	-15.57
Operating Cash Flow to Interest Expense	1.59	2.24	1.82	-4.08	-1.49	0.30	-4.36	-26.39	10.25	-4.56
Operating Cash Flow Less CapEx to Interest Expense	0.94	1.22	-0.07	-6.39	-5.12	-13.58	-14.11	-35.29	-20.32	-23.07
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.88	0.88	0.86	0.83	1.08	0.99	0.88	0.77	0.99	0.98
Accounts Receivable Turnover	6.08	6.55	6.48	6.35	7.07	7.05	6.32	5.70	5.71	6.41
Inventory Turnover	1.23	1.17	1.17	1.16	1.62	1.43	1.23	1.03	1.35	1.34
Fixed Asset Turnover	5.35	5.23	5.23	5.14	6.86	6.35	6.01	5.42	7.84	7.95
Accounts Payable Turnover	4.73	5.00	4.98	4.99	6.06	5.65	4.68	4.37	4.57	5.22
Days Sales Outstanding (DSO)	59.99	55.70	56.31	57.47	51.66	51.81	57.76	64.03	63.94	56.93
Days Inventory Outstanding (DIO)	296.21	311.40	311.66	313.34	225.92	255.92	297.68	354.24	270.51	272.77
Days Payable Outstanding (DPO)	77.11	73.07	73.29	73.20	60.25	64.58	77.92	83.58	79.85	69.96
Cash Conversion Cycle (CCC)	279.09	294.04	294.68	297.61	217.33	243.14	277.51	334.69	254.60	259.74
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	574	612	635	659	655	652	653	659	286	282
Invested Capital Turnover	1.30	1.24	1.20	1.15	1.58	1.43	1.28	1.15	1.72	1.65
Increase / (Decrease) in Invested Capital	-81	-40	-18	-0.14	369	370	371	396	37	0.26
Enterprise Value (EV)	738	682	587	632	552	509	673	606	360	331
Market Capitalization	667	596	498	543	495	472	660	611	411	382
Book Value per Share	$13.17	$13.78	$14.55	$15.25	$16.29	$16.75	$17.51	$18.22	$16.84	$16.67
Tangible Book Value per Share	$5.48	$5.93	$6.47	$7.02	$7.79	$8.16	$8.82	$9.31	$10.90	$10.73
Total Capital	660	644	664	689	693	685	691	709	337	334
Total Debt	157	118	118	118	94	70	51	45	0.00	0.00
Total Long-Term Debt	157	112	113	115	93	70	51	45	0.00	0.00
Net Debt	71	86	89	89	57	36	13	-4.97	-51	-52
Capital Expenditures (CapEx)	9.67	5.32	9.34	11	16	22	12	11	7.00	5.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	179	198	206	222	219	208	220	223	122	118
Debt-free Net Working Capital (DFNWC)	265	231	235	251	256	241	258	272	172	169
Net Working Capital (NWC)	265	224	230	248	255	241	258	272	172	169
Net Nonoperating Expense (NNE)	21	14	16	15	9.35	12	14	19	-0.67	6.67
Net Nonoperating Obligations (NNO)	71	86	89	89	57	36	13	-4.97	-51	-52
Total Depreciation and Amortization (D&A)	30	20	19	19	24	22	24	26	8.16	8.32
Debt-free, Cash-free Net Working Capital to Revenue	22.38%	25.29%	26.73%	29.26%	29.35%	31.04%	36.75%	42.02%	26.41%	25.37%
Debt-free Net Working Capital to Revenue	33.10%	29.45%	30.48%	33.15%	34.41%	36.08%	43.04%	51.46%	37.41%	36.51%
Net Working Capital to Revenue	33.10%	28.65%	29.87%	32.73%	34.24%	36.08%	43.04%	51.46%	37.41%	36.51%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.76)	($0.71)	($0.88)	($0.95)	($0.57)	($0.77)	($1.07)	($1.71)	($0.35)	($0.53)
Adjusted Weighted Average Basic Shares Outstanding	38.13M	38.49M	38.02M	37.74M	36.73M	37.25M	36.76M	35.73M	20.05M	20.09M
Adjusted Diluted Earnings per Share	($0.76)	($0.71)	($0.88)	($0.95)	($0.57)	($0.77)	($1.07)	($1.71)	($0.35)	($0.53)
Adjusted Weighted Average Diluted Shares Outstanding	38.13M	38.49M	38.02M	37.74M	36.73M	37.25M	36.76M	35.73M	20.05M	20.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.02M	38.21M	38.17M	37.53M	37.41M	36.76M	36.74M	36.54M	36.46M	20.01M
Normalized Net Operating Profit after Tax (NOPAT)	-8.03	-13	-17	-21	-13	-17	-26	-42	-7.73	-4.05
Normalized NOPAT Margin	-3.73%	-6.73%	-8.78%	-10.89%	-6.44%	-9.30%	-13.71%	-23.86%	-6.32%	-3.55%
Pre Tax Income Margin	-13.78%	-13.55%	-16.29%	-18.65%	-11.03%	-15.43%	-20.28%	-34.43%	-5.72%	-8.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.99	-4.11	-5.55	-6.72	-3.90	-17.01	-28.95	-45.80	-29.51	-32.83
NOPAT to Interest Expense	-0.54	-2.54	-3.53	-4.51	-2.85	-10.86	-20.25	-32.43	-33.76	-14.62
EBIT Less CapEx to Interest Expense	-1.64	-5.13	-7.44	-9.03	-7.53	-30.89	-38.71	-54.70	-60.08	-51.34
NOPAT Less CapEx to Interest Expense	-1.19	-3.56	-5.42	-6.82	-6.48	-24.74	-30.01	-41.33	-64.33	-33.13
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	-17.77%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-17.77%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Orthofix Medical's Financials

When does Orthofix Medical's financial year end?

According to the most recent income statement we have on file, Orthofix Medical's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Orthofix Medical's net income changed over the last 2 years?

Orthofix Medical's net income appears to be on an upward trend, with a most recent value of -$126.00 million in 2024, rising from -$19.75 million in 2022. The previous period was -$151.40 million in 2023. See where experts think Orthofix Medical is headed by visiting Orthofix Medical's forecast page.

What is Orthofix Medical's operating income?

Orthofix Medical's total operating income in 2024 was -$84.62 million, based on the following breakdown:

Total Gross Profit: $545.89 million
Total Operating Expenses: $630.50 million

How has Orthofix Medical revenue changed over the last 2 years?

Over the last 2 years, Orthofix Medical's total revenue changed from $460.71 million in 2022 to $799.49 million in 2024, a change of 73.5%.

How much debt does Orthofix Medical have?

Orthofix Medical's total liabilities were at $390.17 million at the end of 2024, a 19.5% increase from 2023, and a 220.4% increase since 2022.

How much cash does Orthofix Medical have?

In the past 2 years, Orthofix Medical's cash and equivalents has ranged from $33.11 million in 2023 to $83.24 million in 2024, and is currently $83.24 million as of their latest financial filing in 2024.

How has Orthofix Medical's book value per share changed over the last 2 years?

Over the last 2 years, Orthofix Medical's book value per share changed from 16.84 in 2022 to 13.17 in 2024, a change of -21.8%.

Related Companies

This page (NASDAQ:OFIX) was last updated on 5/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orthofix Medical (OFIX) Financials

Frequently Asked Questions About Orthofix Medical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orthofix Medical (OFIX) Financials

Annual Income Statements for Orthofix Medical

Quarterly Income Statements for Orthofix Medical

Annual Cash Flow Statements for Orthofix Medical

Quarterly Cash Flow Statements for Orthofix Medical

Annual Balance Sheets for Orthofix Medical

Quarterly Balance Sheets for Orthofix Medical

Annual Metrics And Ratios for Orthofix Medical

Quarterly Metrics And Ratios for Orthofix Medical

Frequently Asked Questions About Orthofix Medical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools